Cargando…

Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile

It is unclear why medulloblastoma patients receiving similar treatments experience different outcomes. Transcriptomic profiling identified subgroups with different prognoses, but in each subgroup, individuals remain at risk of incurable recurrence. To investigate why similar-appearing tumors produce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malawsky, Daniel Shiloh, Weir, Seth J., Ocasio, Jennifer Karin, Babcock, Benjamin, Dismuke, Taylor, Cleveland, Abigail H., Donson, Andrew M., Vibhakar, Rajeev, Wilhelmsen, Kirk, Gershon, Timothy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139976/ https://www.ncbi.nlm.nih.gov/pubmed/34021242 http://dx.doi.org/10.1038/s42003-021-02099-w

Ejemplares similares

scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
por: Ocasio, Jennifer Karin, et al.
Publicado: (2019)

Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
por: Ocasio, Jennifer Karin, et al.
Publicado: (2022)

EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA
por: Donson, Andrew, et al.
Publicado: (2021)

EMBR-15. PRC2 COMPLEX ENFORCES NEURONAL LINEAGE AND SUPPRESSES TUMOR GROWTH IN SHH MEDULLOBLASTOMA
por: Cleveland, Abigail, et al.
Publicado: (2021)

MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq
por: Donson, Andrew, et al.
Publicado: (2020)

MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture
por: Willard, Nicholas, et al.
Publicado: (2022)

MPS1 kinase as a potential therapeutic target in medulloblastoma
por: Alimova, Irina, et al.
Publicado: (2016)

PRC2 disruption in cerebellar progenitors produces cerebellar hypoplasia and aberrant myoid differentiation without blocking medulloblastoma growth
por: Cleveland, Abigail H., et al.
Publicado: (2023)

A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma
por: Wang, Dong, et al.
Publicado: (2021)

MODL-03. ADAPTING PALBOCICLIB FOR MEDULLOBLASTOMA THERAPY BY IMPROVING DRUG DELIVERY AND ADDRESSING RESISTANCE
por: Dismuke, Taylor, et al.
Publicado: (2020)

Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq–guided combination with sapanisertib
por: Lim, Chaemin, et al.
Publicado: (2022)

EPCT-19. DRUG RESISTANCE IN MEDULLOBLASTOMA ADDRESSED WITH OLIG2 INHIBITOR, CT-179
por: Dismuke, Taylor, et al.
Publicado: (2021)

MBRS-08. SONIC HEDGEHOG SIGNALING PRIMES CEREBELLAR GRANULE NEURON PROGENITORS, THE CELL OF ORIGIN FOR MEDULLOBLASTOMA, FOR APOPTOSIS BY INDUCING PRO APOPTOTIC BIM
por: Cleveland, Abigail, et al.
Publicado: (2020)

BIMG-18. ELEVATED CYSTATHIONINE IN MEDULLOBLASTOMA DEMONSTRATES TUMOR-SPECIFIC METHIONINE METABOLISM
por: Tikunov, Andrey, et al.
Publicado: (2021)

Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma
por: Bhatia, Shilpa, et al.
Publicado: (2017)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MEDB-70. Metabolism mediated radiation resistance in MYC-driven Medulloblastoma
por: Veo, Bethany, et al.
Publicado: (2022)

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells
por: Harris, Peter S, et al.
Publicado: (2012)

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma
por: Harris, Peter S, et al.
Publicado: (2014)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

Spatial heterogeneity in medulloblastoma
por: Morrissy, A Sorana, et al.
Publicado: (2017)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

HGG-18. SINGLE CELL RNA-SEQ ANALYSIS OF PEDIATRIC HIGH-GRADE GLIOMA PATIENT SAMPLES IDENTIFIES COMMON GLIAL AND IMMUNE CELL TYPES THAT HELP TO EXPLAIN HETEROGENEITY AND TUMORIGENESIS
por: DeSisto, John, et al.
Publicado: (2023)

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma
por: Prince, Eric W., et al.
Publicado: (2016)

A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer
por: Lagerweij, Tonny, et al.
Publicado: (2016)

Limitations of radiosensitization by direct telomerase inhibition to treat high-risk medulloblastoma
por: Sengupta, Satarupa, et al.
Publicado: (2023)

MDB-26. CDK8 IS AN ONCOGENE IN GROUP 3 MEDULLOBLASTOMA THAT IMPACTS PROTEIN TRANSLATION BY REGULATING THE TRANSCRIPTIONAL ACTIVITY OF RIBOSOMAL GENES
por: Wang, Dong, et al.
Publicado: (2023)

Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma
por: Suzuki, Hiromichi, et al.
Publicado: (2019)

NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells
por: Douyère, Manon, et al.
Publicado: (2022)

MicroRNA 128a Increases Intracellular ROS Level by Targeting Bmi-1 and Inhibits Medulloblastoma Cancer Cell Growth by Promoting Senescence
por: Venkataraman, Sujatha, et al.
Publicado: (2010)

MBRS-67. ROLE OF CYCLIN DEPENDENT KINASE-9 IN Myc-ENHANCED MEDULLOBLASTOMA
por: Madhavan, Krishna, et al.
Publicado: (2020)

Subtypes of medulloblastoma have distinct developmental origins
por: Gibson, Paul, et al.
Publicado: (2010)

Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis
por: Purvis, Ian J., et al.
Publicado: (2019)

MiR‐1253 exerts tumor‐suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7‐H3)
por: Kanchan, Ranjana K., et al.
Publicado: (2020)

Cryptic Genetic Variation in Evolutionary Developmental Genetics
por: Paaby, Annalise B., et al.
Publicado: (2016)

Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup
por: dos Santos Klinger, Paulo Henrique, et al.
Publicado: (2020)

MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)

Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179
por: Li, Yuchen, et al.
Publicado: (2023)

XRT-02. SINGLE-CELL RNA SEQUENCING IDENTIFIES FUNCTIONAL MACROPHAGE SUBSETS THAT ARE ENRICHED IN RESPONSE TO DIFFERENTIAL PHAGOCYTOSIS INDUCTION AGAINST GLIOMA
por: Lakshmanachetty, Senthilnath, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7m5vg6lerive6oqb14mqel57vi